Search on our site

i.e.: vidatox, lung cancer or monoclonal antibodies. You can use any regular expression or word chain. Expressions with special character (') won't produce any result.

 followus black
Seguici su Facebook Seguici su Twitter Seguici su Linkedin Seguici su Google Seguici su YouTube

Blog AirGoesMagic

Su questo blog è possibile parlare di temi aeronautici e di salute che riguardano i nostri programmi.

  • Home
    Home This is where you can find all the blog posts throughout the site.
  • Categories
    Categories Displays a list of categories from this blog.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Bloggers
    Bloggers Search for your favorite blogger from this site.
  • Team Blogs
    Team Blogs Find your favorite team blogs here.
  • Login
    Login Login form

Interferon Alpha-2b Recombinant in Multiple Sclerosis (Ms). Preliminary Report

by in Programma Neurologico (CIREN)
  • Font size: Larger Smaller
  • Hits: 2819
  • 0 Comments
  • Subscribe to this entry
  • Print
2819

 

On 2009, at the Neurological Institute of Havana, Cuba, was conducted a double-blind, placebo-controlled study of 225 patients with clinical definite relapsing remitting (RR) MS and brain MRI confirmed. Patients were randomly assigned to receive intramuscular Interferon (IFN) alpha-2b (Heberón alfa R) 20 million IU (high dose), 6 million IU (low dose) or placebo weekly for 2 years.

The primary outcome measures were change in the yearly excerbation rate and proportion of exacerbationfree patients. Neurologic disability and changes in brain MRI were the secondary outcome measures. We did an analysis by intention to treat that included the first 17 patients at the 2-year study period. Treated low dose group showed a reduction in yearly exacerbation rate from 2,8 ± 1,1 to 0(p= 0.028) vs placebo, the high dose group from 2,3 ± 0.5 to 0,5 ±0,8(p= 0.028) vs placebo, whereas the placebo group from 2,8 ±1,1 to 1,6 ± 2,1, reflecting a reduction in relapse rate in IFN groups. Six patients in the low dose IFN alpha group were exacerbation free throughout 2-year period, 4/6 patients in the high dose whereas 2/5 in the placebo group.

Neurologic disability as measured by the Expanded Disability Status Scale (EDSS score) decreased from 5,2 ± 1 to 4,8 ± 1,8 in the low IFN dose, increased from 3,8 ±1,8 to 4,8 ± 2,2 in high dose group so long as in the placebo group from 5 ± 2 to 5,2 ± 2,9 (not statistically significant). Our results suggest that IFN alpha, mainly low dose group, produced a significant decreased in yearly exacerbation rate in RR-MS patients.

 

Comments

  • No comments made yet. Be the first to submit a comment

Leave your comment

Guest Saturday, 26 September 2020